Barclays analyst Matt Miksic raised the firm’s price target on Medtronic (MDT) to $116 from $111 and keeps an Overweight rating on the shares. The firm cites an increased target multiple for the boost to put the stock in line with the recent increase in peers.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- 3 Best Dividend Aristocrat Stocks to Buy Now, 01/07/2026
- CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
- Medtronic upgraded to Outperform from Market Perform at William Blair
- Medtronic: Fairly Valued on Aligned EPS Guidance and Higher Interest Costs, Justifying a Hold Rating
- Medtronic put volume heavy and directionally bearish